Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 18 of 18

List	Outcome	Time frame	Description
Primary	Reduction in Primary Joint Contracture to 5° or Less	Within 30 days after last injection	Successfully treated or clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Secondary	Clinical Improvement in Primary Joint After the Last Injection	Baseline, Within 30 days after last injection	Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Secondary	Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
Secondary	Change From Baseline Range of Motion in Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Change in degree of range of motion in primary joint measured as last available post-injection range of motion - baseline range of motion
Secondary	Time to Reach Clinical Success in Primary Joint	Within 30 days after last injection	Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
Secondary	Clinical Success in Primary Joint After the First Injection	Within 30 days after first injection	Clinical success in primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Secondary	Clinical Improvement in Primary Joint After the First Injection	Baseline, Within 30 days after first injection	Clinical improvement in primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Secondary	Percent Reduction From Baseline Contracture of Primary Joint After the First Injection	Baseline, Day 30 after first injection	Percent change in degree of contracture of primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
Secondary	Change From Baseline Range of Motion in Primary Joint After the First Injection	Baseline, Day 30 after first injection	Change in degree of range of motion in primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion
Secondary	Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection	Within 30 days after last injection	Successfully treated or clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Secondary	Clinical Improvement in Non-Primary Joint After the Last Injection	Baseline, Within 30 days after last injection	Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Secondary	Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture)/baseline contracture
Secondary	Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion - baseline range of motion
Secondary	Time to Reach Clinical Success in Non-Primary Joint	Within 30 days after last injection	Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
Secondary	Clinical Success in Non-Primary Joint After the First Injection	Within 30 days after first injection	Clinical success in non-primary joint defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
Secondary	Clinical Improvement in Non-Primary Joint After the First Injection	Baseline, Within 30 days after first injection	Clinical improvement in non-primary joint defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
Secondary	Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection	Baseline, Day 30 after first injection	Percent change in degree of contracture of non-primary joint measured as 100 \* (baseline contracture - last available post-injection contracture prior to next injection)/baseline contracture
Secondary	Change From Baseline Range of Motion in Non-Primary Joint After the First Injection	Baseline, Day 30 after first injection	Change in degree of range of motion in non-primary joint measured as last available post-injection range of motion prior to the next injection - baseline range of motion

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00533273/registered

API reference For AI assistants